Quoin pharmaceuticals announces additional positive interim data from ongoing open-label netherton syndrome clinical study

Ashburn, va., jan. 06, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces additional positive interim clinical data from one of its ongoing netherton syndrome clinical studies.

QNRX Ratings Summary

QNRX Quant Ranking